Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06338995 · ClinicalTrials.gov registry record · Phase 3
A Study of Lebrikizumab (LY3650150) in Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP)
A Phase 3 study of Chronic Rhinosinusitis With Nasal Polyps (CRSwNP), sponsored by Eli Lilly and Company.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 510
- Enrollment target
- 20
- Study locations
NCT06338995: Recruiting Phase 3 study of Chronic Rhinosinusitis With Nasal Polyps (CRSwNP), sponsored by Eli Lilly and Company.
NCT06338995 is a Phase 3 study of Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) that is actively recruiting participants, run by Eli Lilly and Company. The registered enrollment target is 510 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (34% lower). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06338995, a Phase 3 study of Chronic Rhinosinusitis With Nasal Polyps (CRSwNP), is actively recruiting participants, sponsored by Eli Lilly and Company.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 510 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main purpose of this study is to evaluate the efficacy and safety of lebrikizumab in participants with chronic rhinosinusitis and nasal polyps treated with intranasal corticosteroids. The study will last about 18 months.
Primary Outcome
NCS severity is rated by study participants using a 4-point scale (range from 0 to 3), where 0 corresponds to no symptoms and 3 corresponds to severe symptoms. Study participants are asked to record the severity of nasal congestion for the previous 24 hours. This assessment will be collected in the participant eDiary.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG LY3650150
- DRUG Standard therapy for INCS
Study Locations (20)
California
- Keck Medicine of USC - Arcadia
- University of California, Irvine - Irvine
- DaVinci Research LLC - Roseville
- Breathe Clear Institute - Torrance
Florida
- Orlando ENT & Allergy - Orlando
- NuLine Clinical Trial Center - Pompano Beach
- University of South Florida - Tampa
Alabama
- AllerVie Clinical Research - Birmingham
- University of Alabama at Birmingham - Birmingham
Illinois
- Entopy Research LLC - Chicago
- Chicago ENT - Chicago
Missouri
- University of Missouri - Columbia
- Washington University School of Medicine - St Louis
Colorado
- Colorado ENT & Allergy - Colorado Springs
Idaho
- Treasure Valley Medical Research - Boise
Louisiana
- South Louisiana Ear, Nose, Throat & Facial Plastic Surgery - PPDS - Mandeville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 510 participants |
| Start Date | 2024-04-29 |
| Est. Completion | 2028-03 |
| Phase | Phase 3 |
What NCT06338995 shows while recruiting
NCT06338995 is an interventional study that assigns participants to a tested intervention. The registered 510 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (34% lower).
The record links to 1 condition, with Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT06338995 names 20 study sites across 12 states, led by California, Florida, Alabama.
Frequently Asked Questions
What is clinical trial NCT06338995 about?
NCT06338995 is a clinical study titled "A Study of Lebrikizumab (LY3650150) in Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP)". The main purpose of this study is to evaluate the efficacy and safety of lebrikizumab in participants with chronic rhinosinusitis and nasal polyps treated with intranasal corticosteroids. The study will last about 18 months.
What is the current status of trial NCT06338995?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 510 participants. The study started on 2024-04-29. Estimated completion is 2028-03.
What conditions does trial NCT06338995 study?
This clinical trial studies the following conditions: Chronic Rhinosinusitis With Nasal Polyps (CRSwNP).
What interventions are being tested in trial NCT06338995?
The interventions under investigation include: Placebo (DRUG), LY3650150 (DRUG), Standard therapy for INCS (DRUG).
Who is sponsoring clinical trial NCT06338995?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06338995 being conducted?
This trial has 20 study locations across Alabama, California, Colorado, Florida, Idaho. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06338995's enrollment target sits among peer trials
510 729th of 2000 higher than 1,265 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03922542 · 510 participants · Phase 2
Comparison of Standard vs. Accelerated Corneal Crosslinking
- NCT04634552 · 510 participants · Phase 2
A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
- NCT05164744 · 510 participants
Cardiac Magnetic Resonance Tissue Characterization in COVID-19 Survivors
- NCT05451004 · 510 participants · Phase 3
SPECT-CT Guided ELEctive Contralateral Neck Treatment for Patients With Lateralized Oropharyngeal Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI